Trial
NCT01944943
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
The Lymphoma Academic Research Organisation
Collaborators
Roche Pharma AG
Condition
Diffuse Large B-cell Lymphoma
Intervention
Vismodegib
Why stopped
lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-13